{"id":"hrze","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Hepatotoxicity"},{"rate":"0.5-2","effect":"Peripheral neuropathy"},{"rate":"5-15","effect":"Gastrointestinal disturbance"},{"rate":"null","effect":"Hyperuricemia"},{"rate":"0.1-1","effect":"Optic neuritis (ethambutol-related)"},{"rate":"1-5","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HRZE combines isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB), each targeting different aspects of Mycobacterium tuberculosis metabolism and cell wall integrity. Isoniazid inhibits mycolic acid synthesis, rifampicin blocks RNA polymerase, pyrazinamide disrupts energy metabolism in acidic environments, and ethambutol inhibits arabinosyl transferases. The combination provides rapid bactericidal activity and reduces the emergence of drug-resistant strains.","oneSentence":"HRZE is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:54.994Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (drug-susceptible, pulmonary and extrapulmonary)"}]},"trialDetails":[{"nctId":"NCT07350174","phase":"PHASE2","title":"Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis","status":"NOT_YET_RECRUITING","sponsor":"BioVersys AG","startDate":"2026-03-30","conditions":"Tuberculosis Meningitis","enrollment":64},{"nctId":"NCT07073638","phase":"PHASE2","title":"Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis","status":"RECRUITING","sponsor":"Thirty Respiratory Limited","startDate":"2025-10-13","conditions":"Pulmonary Tuberculoses","enrollment":24},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT06041919","phase":"PHASE2","title":"Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis","status":"TERMINATED","sponsor":"Thirty Respiratory Limited","startDate":"2023-09-27","conditions":"Rifampicin Susceptible Pulmonary Tuberculosis","enrollment":20},{"nctId":"NCT05686356","phase":"PHASE2, PHASE3","title":"A Pan-TB Regimen Targeting Host and Microbe","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-07-28","conditions":"Tuberculosis","enrollment":352},{"nctId":"NCT06748937","phase":"PHASE2","title":"A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide","status":"RECRUITING","sponsor":"TASK Applied Science","startDate":"2025-03-03","conditions":"Tuberculosis","enrollment":60},{"nctId":"NCT05971602","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2023-07-26","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT06058299","phase":"PHASE2","title":"Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Global Alliance for TB Drug Development","startDate":"2023-10-24","conditions":"Pulmonary TB, Pulmonary Tuberculosis, Drug Sensitive Tuberculosis","enrollment":309},{"nctId":"NCT04176250","phase":"PHASE2","title":"Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Gates Medical Research Institute","startDate":"2020-01-16","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT03338621","phase":"PHASE2, PHASE3","title":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2018-07-30","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":455},{"nctId":"NCT03160638","phase":"PHASE2","title":"Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2018-02-01","conditions":"Tuberculosis, Pulmonary","enrollment":24},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT04694586","phase":"PHASE2","title":"Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide","status":"SUSPENDED","sponsor":"University Hospital, Linkoeping","startDate":"2022-11-30","conditions":"Tuberculosis, Pulmonary","enrollment":40},{"nctId":"NCT05917340","phase":"PHASE3","title":"Intensified Short Course Regimen for TBM in Adults","status":"NOT_YET_RECRUITING","sponsor":"Indian Council of Medical Research","startDate":"2024-03","conditions":"Tuberculous Meningitis","enrollment":372},{"nctId":"NCT03456102","phase":"PHASE2","title":"Statin Adjunctive Therapy for TB","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-03-09","conditions":"Tuberculosis","enrollment":16},{"nctId":"NCT04044001","phase":"PHASE1, PHASE2","title":"BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2019-11-15","conditions":"Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis","enrollment":77},{"nctId":"NCT02467608","phase":"PHASE2, PHASE3","title":"Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2012-12-06","conditions":"Pulmonary Tuberculosis","enrollment":557},{"nctId":"NCT04629378","phase":"PHASE2","title":"Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2020-08-17","conditions":"Tuberculosis","enrollment":22},{"nctId":"NCT03787940","phase":"NA","title":"Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2019-03-04","conditions":"Tuberculous Meningitis","enrollment":676},{"nctId":"NCT02231229","phase":"PHASE4","title":"Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-07-23","conditions":"Tuberculosis","enrollment":204},{"nctId":"NCT02193776","phase":"PHASE2","title":"A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2014-10-23","conditions":"Tuberculosis","enrollment":240},{"nctId":"NCT02342886","phase":"PHASE3","title":"Shortening Treatment by Advancing Novel Drugs","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2015-02","conditions":"Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant","enrollment":284},{"nctId":"NCT02279875","phase":"PHASE2","title":"A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2014-11","conditions":"Pulmonary Tuberculosis","enrollment":113},{"nctId":"NCT02457208","phase":"PHASE1","title":"PK Study of Anti-TB Drugs","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-07-07","conditions":"Tuberculosis","enrollment":61},{"nctId":"NCT01785186","phase":"PHASE2","title":"Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2013-04","conditions":"Tuberculosis, Pulmonary","enrollment":365},{"nctId":"NCT00728507","phase":"PHASE2","title":"Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2009-11","conditions":"Tuberculosis","enrollment":121},{"nctId":"NCT02121314","phase":"PHASE2","title":"HRZE Fasted/Fed in Newly Diagnosed TB","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2013-07","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT00144417","phase":"PHASE2","title":"TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2006-02","conditions":"Tuberculosis","enrollment":433}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"PULMONARY TUBERCULOSIS"}],"_approvalHistory":[],"publicationCount":105,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["INH, RMP, PZA and EMB","isoniazid","H","rifampicin","R"],"phase":"phase_3","status":"active","brandName":"HRZE","genericName":"HRZE","companyName":"Global Alliance for TB Drug Development","companyId":"global-alliance-for-tb-drug-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HRZE is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production. Used for Tuberculosis (drug-susceptible, pulmonary and extrapulmonary).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}